BridgeBio's ATTR-CM Trial Demonstrates Significant Mortality and Hospitalization Reduction
TL;DR
BridgeBio has announced positive results from its Phase III trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial showed improvements in mortality, cardiovascular-related hospitalizations, a six-minute walk test, and a biomarker of the disease. Patients receiving the drug had an 81% survival rate at 30 months, compared to 74% on placebo, and the drug reduced hospitalization rates by 50%.
- BridgeBio’s ATTR-CM trial shows mortality and hospitalization benefit Endpoints News
- BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) Yahoo Finance
- BridgeBio Pharma's heart disease drug meets main goal in late-stage study AOL
- 2 Nasdaq Stocks That Could Soar This Week The Motley Fool
- BridgeBio Pharma's heart disease drug meets main goal in late-stage study Reuters
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News